{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T09:27:09Z","timestamp":1794994029088,"version":"4.9.1"},"reference-count":49,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,4,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Autologous hematopoietic cell transplantation (HCT) followed by nonmyeloablative allogeneic HCT (auto\/alloHCT) provides cytoreduction and graft-versus-myeloma effects. We report on long-term outcomes of 102 patients with multiple myeloma who received auto\/alloHCT with a median follow-up of 6.3 years. Treatment consisted of high-dose melphalan and autograft followed by 2-Gy total body irradiation, with or without fludarabine, and alloHCT from human leukocyte antigen-identical siblings. Postgrafting immunosuppressive agent was cyclosporine or tacrolimus and mycophenolate mofetil. Forty-two percent of patients developed grade 2 to 4 acute graft-versus-host disease (GVHD) and 74% extensive chronic GVHD. Five-year nonrelapse mortality after allografting was 18%, 95% related to GVHD or infections. Among 95 patients with detectable disease, 59 achieved complete remissions. Median time to progression was 5 years. Median overall survival (OS) was not reached. Median progression-free survival (PFS) was 3 years. Five-year OS and PFS were 64% and 36%, respectively. Seventy-three patients receiving autoHCT within 10 months from treatment initiation had 5-year OS of 69% and PFS of 37%. In multivariate analysis, \u03b2-2-microglobulin of more than 3.5 \u03bcg\/mL at diagnosis and auto\/alloHCT more than 10 months after treatment initiation correlated with shorter OS (P = .03 and P = .02) and PFS (P = .04 and P = .03), whereas Karnofsky scores less than 90% at allotransplantation correlated with shorter PFS only (P = .005). Long-term disease control and GVHD remain key issues.<\/jats:p>","DOI":"10.1182\/blood-2008-07-170746","type":"journal-article","created":{"date-parts":[[2008,11,17]],"date-time":"2008-11-17T21:39:09Z","timestamp":1226957949000},"page":"3383-3391","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":82,"title":["Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting"],"prefix":"10.1182","volume":"113","author":[{"given":"Marcello","family":"Rotta","sequence":"first","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry E.","family":"Storer","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"University of Washington, Seattle;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firoozeh","family":"Sahebi","sequence":"additional","affiliation":[{"name":"City of Hope National Medical Center\/Southern California Kaiser Permanente Medical Group, Duarte, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith A.","family":"Shizuru","sequence":"additional","affiliation":[{"name":"Stanford University, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetto","family":"Bruno","sequence":"additional","affiliation":[{"name":"University of Turin, Turin, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thoralf","family":"Lange","sequence":"additional","affiliation":[{"name":"University of Leipzig, Leipzig, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward D.","family":"Agura","sequence":"additional","affiliation":[{"name":"Baylor University, Dallas, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"McSweeney","sequence":"additional","affiliation":[{"name":"Rocky Mountain Cancer Center, Denver, CO;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Pulsipher","sequence":"additional","affiliation":[{"name":"University of Utah, Salt Lake City;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parameswaran","family":"Hari","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin, Milwaukee;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T.","family":"Maziarz","sequence":"additional","affiliation":[{"name":"Oregon Health & Science University, Portland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R.","family":"Chauncey","sequence":"additional","affiliation":[{"name":"Puget Sound VA Medical Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick R.","family":"Appelbaum","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"University of Washington, Seattle;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed L.","family":"Sorror","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Bensinger","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"University of Washington, Seattle;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda M.","family":"Sandmaier","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"University of Washington, Seattle;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer F.","family":"Storb","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"University of Washington, Seattle;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Maloney","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"University of Washington, Seattle;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111713511144200_B1","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/S0140-6736(96)90871-5","article-title":"Graft-versus-myeloma effect in two cases.","volume":"347","author":"Verdonck","year":"1996","journal-title":"Lancet"},{"key":"2019111713511144200_B2","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1182\/blood.V87.3.1196.bloodjournal8731196","article-title":"Graft-versus-myeloma effect: proof of principle.","volume":"87","author":"Tricot","year":"1996","journal-title":"Blood"},{"key":"2019111713511144200_B3","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0140-6736(05)64525-4","article-title":"Graft-versus-myeloma effect [letter].","volume":"348","author":"Aschan","year":"1996","journal-title":"Lancet"},{"key":"2019111713511144200_B4","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1200\/JCO.2000.18.16.3031","article-title":"Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome.","volume":"18","author":"Lokhorst","year":"2000","journal-title":"J Clin Oncol"},{"key":"2019111713511144200_B5","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1182\/blood.V88.12.4711.bloodjournal88124711","article-title":"Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma\u2014a retrospective case-matched study from the European Group for Blood and Marrow Transplantation.","volume":"88","author":"Bj\u00f6rkstrand","year":"1996","journal-title":"Blood"},{"key":"2019111713511144200_B6","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0889-8588(05)70420-2","article-title":"Allogeneic stem cell transplantation for multiple myeloma.","volume":"11","author":"Bensinger","year":"1997","journal-title":"Hematol Oncol Clin North Am"},{"key":"2019111713511144200_B7","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1046\/j.1365-2141.2001.02726.x","article-title":"Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation centres.","volume":"113","author":"Gahrton","year":"2001","journal-title":"Br J Haematol"},{"key":"2019111713511144200_B8","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1200\/JCO.2005.04.5807","article-title":"Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.","volume":"24","author":"Barlogie","year":"2006","journal-title":"J Clin Oncol"},{"key":"2019111713511144200_B9","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1182\/blood-2006-07-036848","article-title":"Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning.","volume":"109","author":"Crawley","year":"2007","journal-title":"Blood"},{"key":"2019111713511144200_B10","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1182\/blood-2002-09-2955","article-title":"Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma.","volume":"102","author":"Maloney","year":"2003","journal-title":"Blood"},{"key":"2019111713511144200_B11","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1182\/blood-2002-01-0131","article-title":"Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma.","volume":"100","author":"Kr\u00f6ger","year":"2002","journal-title":"Blood"},{"key":"2019111713511144200_B12","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma.","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"key":"2019111713511144200_B13","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"2019111713511144200_B14","first-page":"191","article-title":"The clinical evaluation of chemotherapeutic agents in cancer.","volume-title":"Evaluation of Chemotherapeutic Agents","author":"Karnofsky","year":"1949"},{"key":"2019111713511144200_B15","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1182\/blood-2003-02-0482","article-title":"HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies.","volume":"102","author":"Maris","year":"2003","journal-title":"Blood"},{"key":"2019111713511144200_B16","first-page":"234","article-title":"Documentation of engraftment and characterization of chimerism following hematopoietic cell transplantation.","volume-title":"Thomas' Hematopoietic Cell Transplantation","author":"Bryant","year":"2004"},{"key":"2019111713511144200_B17","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma.","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"key":"2019111713511144200_B18","first-page":"825","article-title":"1994 Consensus conference on acute GVHD grading.","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"2019111713511144200_B19","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","article-title":"Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.","volume":"18","author":"Gooley","year":"1999","journal-title":"Stat Med"},{"key":"2019111713511144200_B20","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/sim.4780100313","article-title":"A qualifier Q for the survival function to describe the prevalence of a transient condition.","volume":"10","author":"Pepe","year":"1991","journal-title":"Stat Med"},{"key":"2019111713511144200_B21","doi-asserted-by":"crossref","first-page":"9227","DOI":"10.1200\/JCO.2005.03.0551","article-title":"High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe.","volume":"23","author":"Fermand","year":"2005","journal-title":"J Clin Oncol"},{"key":"2019111713511144200_B22","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.","volume":"348","author":"Child","year":"2003","journal-title":"N Engl J Med"},{"key":"2019111713511144200_B23","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma.","volume":"335","author":"Attal","year":"1996","journal-title":"N Engl J Med"},{"key":"2019111713511144200_B24","first-page":"815a","article-title":"In single versus tandem high dose therapy (HDT) supported with autologous blood stem cell (ABSC) transplantation using unselected or CD34 enriched ABSC: preliminary results of a two by two designed randomized trial in 230 young patients with multiple myeloma (MM) [abstract].","volume":"98","author":"Fermand","year":"2001","journal-title":"Blood"},{"key":"2019111713511144200_B25","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa032290","article-title":"Single versus double autologous stem-cell transplantation for multiple myeloma.","volume":"349","author":"Attal","year":"2003","journal-title":"N Engl J Med"},{"key":"2019111713511144200_B26","doi-asserted-by":"crossref","first-page":"715a","DOI":"10.1182\/blood.V106.11.2545.2545","article-title":"Intensive versus double intensive therapy in untreated multiple myeloma: final analysis of the HOVON 24 trial [abstract].","volume":"106","author":"Sonneveld","year":"2005","journal-title":"Blood"},{"key":"2019111713511144200_B27","first-page":"38","article-title":"Single vs. double high-dose therapy in multiple myeloma: second analysis of the GMMG-HD2 trial [abstract].","volume":"90","author":"Goldschmidt","year":"2005","journal-title":"Haematologica"},{"key":"2019111713511144200_B28","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1200\/JCO.2006.10.2509","article-title":"Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study.","volume":"25","author":"Cavo","year":"2007","journal-title":"J Clin Oncol"},{"key":"2019111713511144200_B29","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1182\/blood-2008-03-145235","article-title":"Thalidomide arm of total therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities.","volume":"112","author":"Barlogie","year":"2008","journal-title":"Blood"},{"key":"2019111713511144200_B30","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1365-2141.2007.06921.x","article-title":"Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2.","volume":"140","author":"Pineda-Roman","year":"2008","journal-title":"Br J Haematol"},{"key":"2019111713511144200_B31","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood-2005-09-3869","article-title":"Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma.","volume":"107","author":"Garban","year":"2006","journal-title":"Blood"},{"key":"2019111713511144200_B32","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1056\/NEJMoa065464","article-title":"A comparison of allografting with autografting for newly diagnosed myeloma.","volume":"356","author":"Bruno","year":"2007","journal-title":"N Engl J Med"},{"key":"2019111713511144200_B33","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1182\/blood-2008-02-141598","article-title":"A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma.","volume":"112","author":"Rosi\u00f1ol","year":"2008","journal-title":"Blood"},{"key":"2019111713511144200_B34","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1046\/j.1365-2141.1999.01651.x","article-title":"Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factors.","volume":"106","author":"Turesson","year":"1999","journal-title":"Br J Haematol"},{"key":"2019111713511144200_B35","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1046\/j.1365-2141.1997.222667.x","article-title":"Health-related quality of life assessed before and during chemotherapy predicts for survival in multiple myeloma. Nordic Myeloma Study Group.","volume":"97","author":"Wisl\u00f8ff","year":"1997","journal-title":"Br J Haematol"},{"key":"2019111713511144200_B36","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma.","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"2019111713511144200_B37","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.1182\/blood-2007-03-081018","article-title":"Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10\u2009549 patients from the International Myeloma Working Group.","volume":"111","author":"Ludwig","year":"2008","journal-title":"Blood"},{"key":"2019111713511144200_B38","doi-asserted-by":"crossref","first-page":"560","DOI":"10.3324\/haematol.12106","article-title":"Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.","volume":"93","author":"Mateos","year":"2008","journal-title":"Haematologica"},{"key":"2019111713511144200_B39","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1080\/10428190410001733772","article-title":"Treatment of relapsed\/refractory multiple myeloma with thalidomide-based regimens: identification of prognostic factors.","volume":"45","author":"Anagnostopoulos","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"2019111713511144200_B40","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1038\/leu.2008.88","article-title":"Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma.","volume":"22","author":"Schilling","year":"2008","journal-title":"Leukemia"},{"key":"2019111713511144200_B41","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1002\/cncr.23375","article-title":"Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation.","volume":"112","author":"Sorror","year":"2008","journal-title":"Cancer"},{"key":"2019111713511144200_B42","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/sj.bmt.1705987","article-title":"Serious or chronic graft-versus-host disease after hematopoietic cell transplantation: a comparison of myeloablative and non-myeloablative conditioning regimens.","volume":"41","author":"Sala-Torra","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"2019111713511144200_B43","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1182\/blood-2005-11-4449","article-title":"Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma.","volume":"107","author":"van de Donk","year":"2006","journal-title":"Blood"},{"key":"2019111713511144200_B44","first-page":"837","article-title":"Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation.","volume":"91","author":"Bruno","year":"2006","journal-title":"Haematologica"},{"key":"2019111713511144200_B45","first-page":"278","article-title":"Efficacy of bortezomib therapy for extramedullary relapse of myeloma after autologous and non-myeloablative allogeneic transplantation.","volume":"90","author":"Patriarca","year":"2005","journal-title":"Haematologica"},{"key":"2019111713511144200_B46","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3324\/haematol.12184","article-title":"HIgh response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma.","volume":"93","author":"El-Cheikh","year":"2008","journal-title":"Haematologica"},{"key":"2019111713511144200_B47","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.exphem.2006.02.020","article-title":"Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status.","volume":"34","author":"Kr\u00f6ger","year":"2006","journal-title":"Exp Hematol"},{"key":"2019111713511144200_B48","doi-asserted-by":"crossref","first-page":"8120","DOI":"10.1073\/pnas.0401563101","article-title":"Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib","volume":"101","author":"Sun","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019111713511144200_B49","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4049\/jimmunol.180.1.163","article-title":"Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition.","volume":"180","author":"Hallett","year":"2008","journal-title":"J Immunol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/113\/14\/3383\/1305470\/zh801409003383.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/113\/14\/3383\/1305470\/zh801409003383.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T06:01:56Z","timestamp":1589090516000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/113\/14\/3383\/24842\/Longterm-outcome-of-patients-with-multiple-myeloma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,2]]},"references-count":49,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2009,4,2]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2008-07-170746","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1145192.604244","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,2]]}}}